The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.
Line Schmidt Tarpgaard
No relevant relationships to disclose
Tormod Kyrre Guren
No relevant relationships to disclose
Bengt Glimelius
Research Funding - Lilly; Merck Serono
Halfdan Sorbye
Consultant or Advisory Role - Merck Serono (U); Merck Serono (U); Novartis; Novartis
Honoraria - Bayer Schering Pharma; Bayer Schering Pharma; Novartis; Novartis; Roche; Roche
Research Funding - Merck Serono; Merck Serono; Sanofi ; Sanofi
Tone Ikdahl
No relevant relationships to disclose
Ib Jarle Christensen
No relevant relationships to disclose
Camilla Qvortrup
No relevant relationships to disclose
Elin Kure
No relevant relationships to disclose
Per Pfeiffer
Consultant or Advisory Role - Merck Serono (U); Roche (U)
Research Funding - Merck Serono; Roche
Kjell Magne Tveit
Research Funding - Merck Serono; Sanofi
Hans J. Nielsen
No relevant relationships to disclose
Nils BrĂ¼nner
No relevant relationships to disclose